Pipeline

NBM-BMX – Mechanism of Action

NBM-BMX: Selective HDAC8 Inhibitor

• Oral, small-molecule epigenetic therapy
• Selectively targets HDAC8, reducing toxicity vs. first-gen HDAC inhibitors

Dual action

• Tumor growth inhibition (cell cycle arrest, apoptosis)• Anti-angiogenesis (blocking VEGF signaling) Demonstrated efficacy in glioblastoma & uveal melanoma preclinical models
• NBM-BMX is being investigated as a potential therapy for patients with advanced solid tumors, glioblastoma, and metastatic uveal melanoma in ongoing Phase 1b/2 clinical trials.
• NBM-BMX has demonstrated selective inhibition of HDAC8 with dual anti-cancer activity, blocking tumor growth and angiogenesis.

The program includes

• NBM-BMX-001/002: Phase 1 studies in advanced solid tumors (completed)
• NBM-BMX-003 (TW): Phase 1b/2 trial in glioblastoma
• NBM-BMX-004 (US): Phase 1b/2 trial in metastatic uveal melanoma

Novelwise has submitted an application to the U.S. FDA for Orphan Drug Designation of NBM-BMX in uveal melanoma, marking an important step toward bringing new treatment options for patients with rare and hard-to-treat cancers.